{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:20:39Z","timestamp":1790230839718,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Secretar\u00eda de Ciencia y Tecnolog\u00eda de la UNR","award":["BIO300"],"award-info":[{"award-number":["BIO300"]}]},{"name":"Secretar\u00eda de Ciencia y Tecnolog\u00eda de la UNR","award":["BIO498"],"award-info":[{"award-number":["BIO498"]}]},{"name":"Agencia Santafesina de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n","award":["AC-2015-0005"],"award-info":[{"award-number":["AC-2015-0005"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ejps.2020.105267","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T20:15:20Z","timestamp":1581538520000},"page":"105267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Preparation and characterization of a new solid form of praziquantel, an essential anthelmintic drug. Praziquantel racemic monohydrate"],"prefix":"10.1016","volume":"146","author":[{"given":"Duvernis","family":"Salazar-Rojas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-8815","authenticated-orcid":false,"given":"Rub\u00e9n M.","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodoro S.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2020.105267_bib0001","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/jps.2600670816","article-title":"Physical characterization of erythromycin: anhydrate, monohydrate, and dihydrate crystalline solids","volume":"67","author":"Allen","year":"1978","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105267_bib0002","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.ijpharm.2015.11.026","article-title":"Elucidating the guest-host interactions and complex formation of praziquantel and cyclodextrin derivatives by 13C and 15 N solid-state NMR spectroscopy","volume":"496","author":"Arr\u00faa","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2020.105267_bib0003","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/jps.20362","article-title":"Application of NIR spectroscopy in polymorphic analysis: study of pseudo-polymorphs stability","volume":"94","author":"Blanco","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105267_bib0004","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1039\/b005746k","article-title":"Polymorphic analysis of a pharmaceutical preparation by NIR spectroscopy","volume":"125","author":"Blanco","year":"2000","journal-title":"Analyst"},{"key":"10.1016\/j.ejps.2020.105267_bib0005","series-title":"Interaction of Praziquantel With Micro- and Nanostructured Inorganic Excipients","author":"Borrego-S\u00e1nchez","year":"2018"},{"key":"10.1016\/j.ejps.2020.105267_bib0006","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s00894-017-3266-3","article-title":"Molecular modeling and infrared and Raman spectroscopy of the crystal structure of the chiral antiparasitic drug praziquantel","volume":"23","author":"Borrego-S\u00e1nchez","year":"2017","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.ejps.2020.105267_bib0007","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejps.2016.04.023","article-title":"Molecular and crystal structure of praziquantel. Spectroscopic properties and crystal polymorphism","volume":"92","author":"Borrego-S\u00e1nchez","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105267_bib0008","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.actatropica.2009.04.006","article-title":"Praziquantel: neglected drug? Ineffective treatment? Or therapeutic choice in cystic hydatid disease?","volume":"111","author":"Bygott","year":"2009","journal-title":"Acta Trop"},{"key":"10.1016\/j.ejps.2020.105267_bib0009","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1017\/S0022149X00007343","article-title":"Tests with a new compound (Praziquantel) against diphyllobothrium latum","volume":"51","author":"Bylund","year":"1977","journal-title":"J. Helminthol."},{"key":"10.1016\/j.ejps.2020.105267_bib0010","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1021\/ja00429a048","article-title":"The effect of crystal packing and defects on desolvation of hydrate crystals of caffeine and L-(-)-1,4-cyclohexadiene-1-alanine","volume":"98","author":"Byrn","year":"1976","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejps.2020.105267_bib0011","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tetasy.2013.11.004","article-title":"A straightforward and efficient synthesis of praziquantel enantiomers and their 4 0 -hydroxy derivatives","volume":"25","author":"Cedillo-Cruz","year":"2013","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejps.2020.105267_bib0012","first-page":"163","article-title":"Development and evaluation of praziquantel solid dispersions in sodium starch glycolate","volume":"12","author":"Chaud","year":"2013","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.ejps.2020.105267_bib0013","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijpharm.2009.05.007","article-title":"Characterization and in vitro release of praziquantel from poly (\u03b5 -caprolactone) implants","volume":"377","author":"Cheng","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2020.105267_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002596","article-title":"Praziquantel treatment decreases schistosoma mansoni. genetic diversity in experimental infections","volume":"7","author":"Coeli","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ejps.2020.105267_bib0015","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.ijpharm.2016.08.009","article-title":"Unexpected solvent impact in the crystallinity of praziquantel\/poly(vinylpyrrolidone) formulations. A solubility, DSC and solid-state NMR study","volume":"511","author":"Costa","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2020.105267_bib0016","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jpba.2017.01.025","article-title":"Biopharmaceutical characterization of praziquantel cocrystals and cyclodextrin complexes prepared by grinding","volume":"137","author":"Cugovcan","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2020.105267_bib0017","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1016\/j.bmc.2017.04.031","article-title":"Medicinal chemistry of antischistosomal drugs: praziquantel and oxamniquine","volume":"25","author":"da Silva","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105267_bib0018","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.molstruc.2018.02.077","article-title":"A synthesis, X-ray crystallographic and vibrational studies of guanidinium o-nitrobenzoate hydrate. New NLO crystal in guanidinium nitrobenzoate family","volume":"1161","author":"Drozd","year":"2018","journal-title":"J. Mol. Struct"},{"key":"10.1016\/j.ejps.2020.105267_bib0019","first-page":"463","article-title":"Anal. Profiles Drug Subst.","volume":"25","author":"El-subbagh","year":"1998","journal-title":"Excip"},{"key":"10.1016\/j.ejps.2020.105267_bib0020","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1021\/cg301314w","article-title":"Cocrystals of active pharmaceutical Ingredients- Praziquantel in combination with oxalic, malonic, succinic, maleic, fumaric, glutaric, adipic, and pimelic acids","volume":"13","author":"Espinosa-Lara","year":"2013","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejps.2020.105267_bib0021","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.xphs.2016.03.040","article-title":"Estimating the aqueous solubility of pharmaceutical hydrates","volume":"105","author":"Franklin","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105267_bib0022","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.01.033","article-title":"In vitro characterization of some biopharmaceutical properties of praziquantel","volume":"295","author":"Gonzales-Esquivel","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2020.105267_bib0023","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1021\/jo971176v","article-title":"NMR chemical shifts of common laboratory solvents as trace impurities","volume":"62","author":"Gottlieb","year":"1997","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejps.2020.105267_bib0024","first-page":"i69","article-title":"Near Infra red reflectance spectroscopic determination of praziquantel","volume":"17","author":"Ibrahim","year":"2001","journal-title":"Anal. Sci."},{"key":"10.1016\/j.ejps.2020.105267_bib0025","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/03639048409040783","article-title":"Hydrate related dissolution characteristics of norfloxacin A","volume":"10","author":"Katdare","year":"1984","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2020.105267_bib0026","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0040-6031(94)01952-D","article-title":"Pharmaceutical hydrates","volume":"248","author":"Khankari","year":"1995","journal-title":"Thermochim. Acta"},{"key":"10.1016\/j.ejps.2020.105267_bib0027","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1166\/jnn.2015.9186","article-title":"Nanostructured lipid carriers as a strategy to improve the in vitro schistosomiasis activity of praziquantel","volume":"15","author":"Kolenyak-Santos","year":"2015","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.ejps.2020.105267_bib0028","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00560463","article-title":"Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics","volume":"14","author":"Leopold","year":"1978","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105267_bib0029","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1002\/jps.20211","article-title":"Structural characterization and enantioseparation of the chiral compound praziquantel","volume":"93","author":"Liu","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105267_bib0030","unstructured":"Management Sciences for Health, World Health Organization, 2011. International drug price indicator guide. Management sciences for health. Cambridge USA, Cambridge (USA). 10.1017\/CBO9781107415324.004."},{"key":"10.1016\/j.ejps.2020.105267_bib0031","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jtbi.2017.08.015","article-title":"Heterogeneity in schistosomiasis transmission dynamics","volume":"432","author":"Mari","year":"2017","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.ejps.2020.105267_bib0032","first-page":"1","article-title":"Pharmacokinetic study of praziquantel enantiomers and its main metabolite R- trans -4-OH-PZQ in plasma, blood and dried blood spots in opisthorchis viverrini-","author":"Meister","year":"2016","journal-title":"Infected Patients"},{"key":"10.1016\/j.ejps.2020.105267_bib0033","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1371\/journal.pntd.0000357","article-title":"Taste, a new incentive to switch to (R) -Praziquantel in schistosomiasis treatment","volume":"3","author":"Meyer","year":"2009","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ejps.2020.105267_bib0034","series-title":"Taste Masking of an Active Pharmaceutical Ingredient For Veterinary Application","author":"Oppel","year":"2008"},{"key":"10.1016\/j.ejps.2020.105267_bib0035","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijpharm.2006.03.028","article-title":"Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel","volume":"318","author":"Passerini","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2020.105267_bib0036","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/acs.cgd.5b01254","article-title":"Chiral resolution of RS -Praziquantel via diastereomeric co-crystal pair formation with L - Malic Acid","volume":"16","author":"S\u00e1nchez-Guadarrama","year":"2015","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejps.2020.105267_bib0037","first-page":"1","article-title":"Drug solubility: importance and enhancement techniques","volume":"2012","author":"Savjani","year":"2012","journal-title":"ISRN Pharm."},{"key":"10.1016\/j.ejps.2020.105267_bib0038","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1002\/jps.20191","article-title":"Dehydration kinetics of piroxicam monohydrate and relationship to lattice energy and structure","volume":"93","author":"Sheth","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105267_bib0039","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1248\/cpb.57.653","article-title":"Hydrogen\u2013Deuterium (H\u2013D) exchange reaction of warfarin in D2O solution","volume":"57","author":"Tode","year":"2009","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejps.2020.105267_bib0040","first-page":"206","article-title":"Structural characterization of praziquantel: a broad spectrum anthelmintic, in powder diffraction","volume":"29","author":"Toro","year":"2014","journal-title":"Powder Diffr."},{"key":"10.1016\/j.ejps.2020.105267_bib0041","unstructured":"United States Pharmacopeia Convention, 2015. United states pharmacopeia and national formulary (USP 39\u2013NF 34). Rockville."},{"key":"10.1016\/j.ejps.2020.105267_bib0042","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.powtec.2010.11.027","article-title":"Influence of needle-shaped drug particles on the solid lipid extrusion process","volume":"207","author":"Witzleb","year":"2011","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejps.2020.105267_bib0043","doi-asserted-by":"crossref","first-page":"e1260","DOI":"10.1371\/journal.pntd.0001260","article-title":"Resolution of praziquantel","volume":"5","author":"Woelfle","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ejps.2020.105267_bib0044","unstructured":"World Health Organization, 2008. WHO model list of essential medicines."},{"key":"10.1016\/j.ejps.2020.105267_bib0045","unstructured":"World Health Organization, 2019. Schistosomiasis [WWW document]. fact sheet n 115."},{"key":"10.1016\/j.ejps.2020.105267_bib0046","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejpb.2018.01.018","article-title":"A new soluble and bioactive polymorph of praziquantel","volume":"127","author":"Zanolla","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720300567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720300567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:53:20Z","timestamp":1760529200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098720300567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":46,"alternative-id":["S0928098720300567"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105267","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preparation and characterization of a new solid form of praziquantel, an essential anthelmintic drug. Praziquantel racemic monohydrate","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105267"}}